OncoDNA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
What changed
OncoDNA
NACE 86.910, Medical imaging and medical laboratories
financial year 2025 compared with 2024filed annual accounts (NBB)
Net result for the year
-€3.8m
2024 · -€5.1m+€1.4m
Equity
-€256,642
2024 · €755,741-€1.0m
Cash
€520,609
2024 · €1.1m-€541,467
Balance sheet total
€5.3m
2024 · €11.4m-€6.1m
Largest movements
Assets
- Financial fixed assets -€1.9m
down €1.9m (-69.1%), from €2.7m to €846,309
- Current investments -€1.7m
no longer reported in 2025 (was €1.7m)
- Intangible fixed assets -€1.5m
down €1.5m (-39.3%), from €3.8m to €2.3m
- Cash -€541,467
down €541,467 (-51.0%), from €1.1m to €520,609
mainly Current portion of long-term debt (-€3.9m) and Net result for the year (-€3.8m)
- Receivables within one year -€431,485
down €431,485 (-24.0%), from €1.8m to €1.4m
of which Trade receivables: -€639,001
Equity and liabilities
- Contributions -€10.5m
down €10.5m (-70.7%), from €14.8m to €4.3m
of which Capital: -€13.2m
- Profit (loss) carried forward +€9.9m
up €9.9m (+63.8%), from -€15.5m to -€5.6m
- Current portion of long-term debt -€3.9m
down €3.9m (-93.0%), from €4.1m to €287,838
- Trade debts -€603,278
down €603,278 (-31.8%), from €1.9m to €1.3m
- Investment grants -€442,144
down €442,144 (-30.0%), from €1.5m to €1.0m
Income statement
- Gross operating margin +€872,738
up €872,738 (+72.3%), from €1.2m to €2.1m
- Staff costs -€192,338
down €192,338 (-7.5%), from €2.6m to €2.4m
- Other operating charges -€184,879
down €184,879 (-37.7%), from €490,005 to €305,126
- Provisions -€147,859
down €147,859, from €40,609 to -€107,250
- Financial income -€85,676
down €85,676 (-13.9%), from €616,529 to €530,852
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Result 2024
-€5.1m
Gross operating margin
+€872,738
Staff costs
+€192,338
Depreciation
+€53,026
Write-downs
-€21,343
Provisions
+€147,859
Other operating charges
+€184,879
Other operating items
-€103
Financial income
-€85,676
Financial charges
-€4,952
Taxes
+€11,691
Result 2025
-€3.8m
raises the resultlowers the resultnot broken down further in the accounts
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
From operations
-€3.0m
Investment
+€3.6m
Financing
-€1.1m
Cash 2024
€1.1m
From operations (derived)
-€3.0m
Net result for the year
-€3.8m
Depreciation
+€1.6m
Stocks and contracts
-€23,863
Receivables within one year
+€431,485
Deferred charges and accrued income
+€42,797
Provisions
-€107,250
Trade debts
-€603,278
Tax, wage and social debts
-€149,672
Other debts
-€184,380
Accrued charges and deferred income
-€148,364
Investment (derived)
+€3.6m
Investment in fixed assets (net)
+€1.9m
Current investments
+€1.7m
Financing
-€1.1m
Debts after one year
-€12,012
Current portion of long-term debt
-€3.9m
Short-term financial debts
-€50,569
Contributions, distributions and other
+€2.8m
Cash 2025
€520,609
brings cash intakes cash out
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €11,387,919 | €5,269,567 | -€6.1m | -53.7% |
| Formation expenses | 20 | €62,781 | €42,373 | -€20,408 | -32.5% |
| Fixed assets | 21/28 | €6,561,322 | €3,155,263 | -€3.4m | -51.9% |
| Intangible fixed assets | 21 | €3,794,680 | €2,302,765 | -€1.5m | -39.3% |
| Tangible fixed assets | 22/27 | €25,238 | €6,190 | -€19,048 | -75.5% |
| Plant, machinery and equipment | 23 | €15,120 | €614 | -€14,507 | -95.9% |
| Furniture and vehicles | 24 | €7,958 | €5,576 | -€2,382 | -29.9% |
| Other tangible fixed assets | 26 | €2,160 | - | -€2,160 | |
| Financial fixed assets | 28 | €2,741,404 | €846,309 | -€1.9m | -69.1% |
| Current assets | 29/58 | €4,763,816 | €2,071,931 | -€2.7m | -56.5% |
| Stocks and contracts in progress | 3 | €119,998 | €143,861 | +€23,863 | +19.9% |
| Stocks | 30/36 | €119,998 | €143,861 | +€23,863 | +19.9% |
| Amounts receivable within one year | 40/41 | €1,799,448 | €1,367,964 | -€431,485 | -24.0% |
| Trade receivables | 40 | €1,724,868 | €1,085,867 | -€639,001 | -37.0% |
| Other amounts receivable | 41 | €74,580 | €282,097 | +€207,517 | +278% |
| Current investments | 50/53 | €1,700,000 | - | -€1.7m | |
| Cash at bank and in hand | 54/58 | €1,062,076 | €520,609 | -€541,467 | -51.0% |
| Deferred charges and accrued income | 490/1 | €82,294 | €39,497 | -€42,797 | -52.0% |
| Total equity and liabilities | 10/49 | €11,387,919 | €5,269,567 | -€6.1m | -53.7% |
| Equity | 10/15 | €755,741 | -€256,642 | -€1.0m | |
| Contributions | 10/11 | €14,788,215 | €4,328,101 | -€10.5m | -70.7% |
| Capital | 10 | €14,788,215 | €1,604,352 | -€13.2m | -89.2% |
| Issued capital | 100 | €14,788,215 | €1,604,352 | -€13.2m | -89.2% |
| Contributions outside capital | 11 | - | €2,723,749 | +€2.7m | |
| Share premium | 1100/10 | - | €2,723,749 | +€2.7m | |
| Profit (loss) carried forward | 14 | -€15,506,234 | -€5,616,358 | +€9.9m | +63.8% |
| Investment grants | 15 | €1,473,759 | €1,031,615 | -€442,144 | -30.0% |
| Provisions and deferred taxes | 16 | €107,250 | - | -€107,250 | |
| Provisions for liabilities and charges | 160/5 | €107,250 | - | -€107,250 | |
| Other liabilities and charges | 164/5 | €107,250 | - | -€107,250 | |
| Amounts payable | 17/49 | €10,524,928 | €5,526,209 | -€5.0m | -47.5% |
| Amounts payable after more than one year | 17 | €3,423,652 | €3,411,641 | -€12,012 | -0.4% |
| Financial debts | 170/4 | €3,423,652 | €3,411,641 | -€12,012 | -0.4% |
| Amounts payable within one year | 42/48 | €6,871,272 | €2,032,929 | -€4.8m | -70.4% |
| Current portion of amounts payable after more than one year | 42 | €4,138,282 | €287,838 | -€3.9m | -93.0% |
| Financial debts | 43 | €50,569 | - | -€50,569 | |
| Credit institutions | 430/8 | €50,569 | - | -€50,569 | |
| Trade debts | 44 | €1,894,750 | €1,291,472 | -€603,278 | -31.8% |
| Suppliers | 440/4 | €1,894,750 | €1,291,472 | -€603,278 | -31.8% |
| Taxes, remuneration and social security | 45 | €495,325 | €345,653 | -€149,672 | -30.2% |
| Taxes | 450/3 | €3,298 | €3,705 | +€406 | +12.3% |
| Remuneration and social security | 454/9 | €492,027 | €341,948 | -€150,078 | -30.5% |
| Other amounts payable | 47/48 | €292,346 | €107,966 | -€184,380 | -63.1% |
| Accrued charges and deferred income | 492/3 | €230,004 | €81,640 | -€148,364 | -64.5% |
| Remuneration, social security and pensions | 62 | €2,559,121 | €2,366,783 | -€192,338 | -7.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,622,079 | €1,569,053 | -€53,026 | -3.3% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) | 631/4 | €44,879 | €66,222 | +€21,343 | +47.6% |
| Provisions for liabilities and charges: additions (uses and reversals) | 635/8 | €40,609 | -€107,250 | -€147,859 | |
| Other operating charges | 640/8 | €490,005 | €305,126 | -€184,879 | -37.7% |
| Non-recurring operating charges | 66A | - | €103 | +€103 | |
| Gross operating margin | 9900 | €1,207,167 | €2,079,905 | +€872,738 | +72.3% |
| Operating profit (loss) | 9901 | -€3,549,526 | -€2,120,131 | +€1.4m | +40.3% |
| Financial income | 75/76B | €616,529 | €530,852 | -€85,676 | -13.9% |
| Recurring financial income | 75 | €616,529 | €530,852 | -€85,676 | -13.9% |
| Financial charges | 65/66B | €2,196,067 | €2,201,019 | +€4,952 | +0.2% |
| Recurring financial charges | 65 | €420,933 | €305,924 | -€115,009 | -27.3% |
| Non-recurring financial charges | 66B | €1,775,134 | €1,895,095 | +€119,961 | +6.8% |
| Profit (loss) for the period before taxes | 9903 | -€5,129,064 | -€3,790,298 | +€1.3m | +26.1% |
| Income taxes | 67/77 | €15,396 | €3,705 | -€11,691 | -75.9% |
| Profit (loss) for the period | 9904 | -€5,144,460 | -€3,794,003 | +€1.4m | +26.3% |
| Profit (loss) for the period to be appropriated | 9905 | -€5,144,460 | -€3,794,003 | +€1.4m | +26.3% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 14 October 2026 via checked.be.